The ThinPrep Difference
HPV Testing with the ThinPrep Pap Test: Out of the Vial
The ThinPrep Pap Test is approved by the U.S. Food and Drug Administration (FDA) as a platform for HPV DNA testing directly from the ThinPrep Pap Test collection vial. A study conducted by the National Cancer Institute concluded that HPV testing is a viable method for determining which patients with borderline pap results are at highest risk for developing cancer. The ThinPrep Pap Test method is also approved/cleared for Chlamydia trachomatis (CT)/ Neisseria Gonorrhea (NG) and Trichomonas testing directly from the ThinPrep Pap Test collection vial.
The ThinPrep Pap Test is the preferred approach when liquid-based cytology is used.1-3
1. Richart R (moderator), Cox J, Twiggs L, Wilkinson E, Wright T. A sea change in diagnosing and managing HPV and cervical cancer - Part 1 (symposium). Contemporary Ob/Gyn. 2002;47:42-4,47-8,51-2,54,56.
2. Wright T, Cox J, Massad LS, Twiggs L, Wilkinson E. 2001 consensus guidelines for the management of women with cervical abnormalities. JAMA. 2002;287:2120-9.
3. Manos MM, et al. Identifying women with cervical neoplasia: Using human papillomavirus DNA testing for equivocal Papanicolaou results. JAMA. 1999;281:1605-10. For additional information on ASC-US management, please see ASCCP "Algorithms from the Consensus Guidelines for the Management of Women with Cervical Cytological Abnormalities."